A new treatment for chronic obstructive pulmonary disease has been launched in the UK.
Aclidinium (Eklira Genuair) is a twice daily maintenance bronchodilator treatment to relieve COPD symptoms in adults.
Aclidinium is a long-acting inhaled muscarinic receptor antagonist, while Genuair is a multi-dose dry powder inhaler.
The inhaler has been specially designed to help patients take the medication correctly and prevent accidental double-dosing or using the inhaler when empty, according to its manufacturer Almirall.
The firm said aclidinium had “demonstrated clinically and statistically significant improvements” in lung function, improved disease specific health status, and a reduction in the rate of moderate to severe exacerbations compared to a placebo in trials.
The most frequently reported adverse events in trials with aclidinium were headache and nasopharyngitis.
The product will cost £28.60.